Strata will help Epizyme identify cancer patients for enrollment in a Phase II trial of its non-Hodgkins lymphoma drug tazemetostat.
Strata will refer castration-resistant prostate cancer patients with BRCA and ATM mutations for potential enrollment in Clovis' Rubraca studies.
The study will provide no-cost tumor sequencing and clinical trial matching to an estimated 100,000 patients with advanced cancers.
The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.
A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.
The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.
In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.